CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 106 enrolled
Drug / intervention
TBAJ-587 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04890535
NCT04890535Phase 1Completed
CompareCT.gov

Phase 1, Partially Blinded, Placebo-Controlled, Randomized, Combined Single Ascending Dose With Food Effect Cohort Trial and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and PK of TBAJ-587 in Healthy Adults

Global Alliance for TB Drug Development·interventional·Posted May 18, 2021·Updated May 19, 2023

In Brief

A Phase 1 clinical trial evaluating TBAJ-587 and Placebo for Tuberculosis. Completed, enrolled 106 participants across 1 site.

Detailed Summary

Phase 1, Partially Blinded, Placebo-Controlled, Randomized, Combined Single Ascending Dose with Food Effect Cohort Trial (Part 1) and Multiple Ascending Dose Trial (Part 2) to Evaluate the Safety, Tolerability, and PK of TBAJ-587 in Healthy Adults

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTuberculosis
CountriesNetherlands
CollaboratorsQPS Holdings LLC

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedMay 18, 2021
Enrollment StartDec 1, 2020
Primary CompletionFeb 27, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.1 years ago

Interventions

TBAJ-587drug

oral suspension

Placebodrug

matching placebo oral suspension for TBAJ-587